Notification Of Un-Audited Financial Results For The Quarter And Half-Year Ended 30Th September, 2017
With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 11th November, 2017, has taken on record the Standalone Un-audited Financial Results of the Company under Ind AS for the quarter and half-year ended 30th September, 2017.... Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Monday, November 13, 2017 at 11:00 a.m. IST to discuss the Un-audited Financial Results for the Q2 Financial Year 2018, to be declared on 11th November, 2017. Closure of Trading Window
With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Board Meeting of our Company will be held on Saturday, the 11th November, 2017 at 10:30 a.m. at the Registered Office, SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and take on record the following matter(s):... Demise
Pursuant to Regulations of SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, we hereby inform you of the sad demise of Dr. K.V. Raghavan, (DIN: 00144054) Independent, Non-Executive Director of the Company, on October 12, 2017. Compliance Certificate Under Regulation 40(10) For The Half-Year Ended 30Th September, 2017
Compliance Certificate under Regulation 40(10) for the half-year ended 30th September, 2017 Statement Of Investor Complaints/Grievances, For The Quarter Ended 30Th September, 2017
Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the statement of Investor complaints/grievances, for the quarter ended 30th September, 2017. Suven spurts over 7% on securing product patent
Shares of Suven Life Sciences surged over 7 per cent in Tuesday's trade as the company has received a patent from New Zealand for a drug used for the treatment of neuro-degenerative diseases. The... Shareholding for the Period Ended September 30, 2017
Suven Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here Press Release / Media Release
Suven Life Sciences secures a Product Patent in New Zealand